Sphingosine 1-Phosphate Receptor Modulators

Sphingosine 1-phosphate Receptor Modulator

Multiple Sclerosis, Relapsing-Remitting

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">ZEPOSIA contains ozanimod, a sphingosine 1-phosphate receptor modulator and is supplied as ozanimod hydrochloride (HCl).</p><p>The chemical name of ozanimod HCl is 5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1<span class="Italics">H</span>-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile, monohydrochloride.</p><p>Ozanimod HCl is a white to off-white solid that is freely soluble in water and alcohol with a molecular weight of 440.92 g/mol.</p><p>The chemical structure is:</p><div class="Figure"><a name="id2594"></a><img alt="zeposia-chem-structure" src="zeposia-chem-structure.jpg"/></div><p>ZEPOSIA capsules are provided as hard gelatin capsules for oral administration, containing 0.23, 0.46, or 0.92 mg of ozanimod (equivalent to 0.25, 0.5, and 1 mg ozanimod HCl, respectively). ZEPOSIA capsules consist of the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium,  magnesium stearate, and microcrystalline cellulose. The capsule shell, imprinted with black ink, contains the following inactive ingredients: black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide.</p></section>

ZEPOSIA

ozanimod

ozanimod 0.92 MG Oral Capsule

Zeposia

ozanimod 0.92 MG Oral Capsule [Zeposia]

ozanimod 0.23 MG Oral Capsule

ozanimod 0.23 MG Oral Capsule [Zeposia]

ozanimod 0.46 MG Oral Capsule

ozanimod 0.46 MG Oral Capsule [Zeposia]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Rinvoq

Entyvio

Zeposia is a medication that can be used to treat relapsing forms of multiple sclerosis or ulcerative colitis in adults. To start taking it, patients need to gradually increase the dose over 7 days. Zeposia reduces the number of lymphocytes in the body to 45% of their initial values. The most frequently reported side effects of the medication are upper respiratory tract infections and increased liver enzyme levels. These side effects can last for up to 3 months after stopping the medication.

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

 Pharmacy List 

Reimbursement Information 

Zeposia HCP Portal 

Formulary Information: Multiple Sclerosis 

Coverage Authorization Request: Multiple Sclerosis 

Letter of Appeal for Patients Currently Receiving MS Treatment

Letter of Appeal for Patients Not Currently Receiving MS Treatment

Letter for Medical Necessity for Patients Currently Receiving MS Treatment

Letter for Medical Necessity for Patients Not Currently Receiving MS Treatment

Formulary Exception Letter: Multiple Sclerosis 

Appeals & Authorizations Kit: Multiple Sclerosis 

Coverage Authorization Request: Ulcerative Colitis 

Coverage Authorization Appeals: Ulcerative Colitis 

Letter of Medical Necessity: Ulcerative Colitis 

Authorization & Appeals Kit: Ulcerative Colitis 

Zeposia Start Form: Ulcerative Colitis

Zeposia Start Form: Multiple Sclerosis

Enroll in Patient Savings Program: Ulcerative Colitis

Enroll in Patient Savings Program: Multiple Sclerosis 

Bridge Program: Ulcerative Colitis 

Bridge Program: Multiple Sclerosis 

Other HCP Resources: Ulcerative Colitis 

Other HCP Resources: Multiple Sclerosis 

About Zeposia: Ulcerative Colitis 

Taking Zeposia: Ulcerative Colitis 

Side Effects: Ulcerative Colitis 

FAQs: Ulcerative Colitis 

Patient Stories: Ulcerative Colitis 

Patient Resources: Ulcerative Colitis 

Zeposia 360 Support Program: Ulcerative Colitis

Instructions For Use: Ulcerative Colitis 

Doctor Discussion Guide: Ulcerative Colitis 

Patient Brochure: Ulcerative Colitis

Zeposia Start Guide: Ulcerative Colitis 

About Zeposia: Multiple Sclerosis 

Taking Zeposia: Multiple Sclerosis 

Side Effects: Multiple Sclerosis

Patient Stories: Multiple Sclerosis 

FAQs: Multiple Sclerosis 

Zeposia 360 Support Program: Multiple Sclerosis 

Patient Resources: Multiple Sclerosis 

Care Partner Resources: Multiple Sclerosis

Instructions For Use: Multiple Sclerosis 

Patient Brochure: Multiple Sclerosis

Patient Brochure (Spanish): Multiple Sclerosis

Doctor Discussion Guide: Multiple Sclerosis 

Zeposia Start Guide: Multiple Sclerosis 